PRODUCT INTRODUCTION
Description
In March 2008, the European Commission granted marketing authorization for dabigatran etexilate (Pradaxa; Boehringer Ingelheim), a direct thrombin inhibitor, for the prevention of venous thromboembolic events in patients who have undergone total hip- or knee-replacement surgery.
RELATED SUPPLIERS
KARPSCHEM LABORATORIES PVT. LTD.
1Y
product:211915-06-9 Dabigatran Etexilate
N-[[2-[[[4-
[[[(Hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methy l]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-β- Alanine Ethyl Ester 96%